Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update

Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update REDWOOD CITY, Calif., November 5, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refracto

Event · Earnings
Original reporting
Published Nov 5, 2026, 9:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RZLT
Bearish
high confidence
Mentioned
$RZLT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RZLTBearishMed
01

Why it matters

The Q1 results show a modest increase in net loss and a decline in cash, which may trigger short‑term selling pressure. However, the company's forward‑looking statements about BLA filing and trial readouts could sustain longer‑term interest.

02

Market read

Primary micro‑cap biotech earnings release with modest downside risk; upcoming regulatory milestones may offset short‑term pressure.

03

What to watch

Potential market optimism from the $5B market opportunity claim and upcoming FDA interactions.

Relevance 7/10Novelty 8/10Timing: after-hours release
AlphAI · Earnings readRZLT · First Quarter Fiscal 2027 · ended September 30, 2026

Rezolute reported a $18.5 million first-quarter fiscal 2027 net loss, ended the quarter with $90.0 million of cash, cash equivalents and marketable securities, and expects tumor HI topline results by mid-December 2026.

→Mixed quarter

Operating expenses declined modestly year over year, but net loss increased and cash, cash equivalents and marketable securities declined from June 30, 2026. The clinical outlook includes an imminent tumor HI readout and an FDA-recommended BLA path for congenital HI, while the congenital HI pivotal study did not meet its primary endpoint.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses, three months ended September 30GAAP$12.81M––
Research and development share-based compensation expense, first quarter fiscal 2027GAAP$1.5M––
General and administrative expenses, three months ended September 30GAAP$6.58M––
General and administrative share-based compensation expense, first quarter fiscal 2027GAAP$1.8M––
Total operating expenses, three months ended September 30GAAP$19.39M––
Loss from operations, three months ended September 30GAAP−$19.39M––
Non-operating income, net, three months ended September 30GAAP$898K––
Net loss, three months ended September 30GAAP−$18.49M––
Basic and diluted net loss per common share, three months ended September 30GAAP$ (0.18 )––
Shares used to compute basic and diluted net loss per common share, three months ended September 30GAAP104.8M––
Cash, cash equivalents and investments in marketable securities, September 30, 2026GAAP$90M––
Cash and cash equivalents, September 30, 2026GAAP$8.15M––
Investments in marketable debt securities, September 30, 2026GAAP81.85M––
Working capital, September 30, 2026GAAP84.37M––
Total assets, September 30, 2026GAAP96.01M––
Accumulated deficit, September 30, 2026GAAP−499.9M––
Total stockholders’ equity, September 30, 2026GAAP85.95M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

2027 outlook

  • NoteTopline results from the upLIFT Phase 3 study in tumor HI are expected by mid-December 2026.
  • NotePlan to submit a BLA for ersodetug for one or potentially both indications in 2027.
  • NotePotential $5 billion combined market opportunity.

What drove it

  • R&D expense decreased primarily due to decreased manufacturing costs for ersodetug and patient affairs costs, partially offset by increased employee-related stock-based compensation expense.
  • G&A expense decreased primarily due to a decrease in professional fees, partially offset by increased employee-related stock-based compensation expense.
  • Enrollment is complete in upLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for tumor HI.
  • 7 of the 8 participants enrolled in the first half of the upLIFT study met the responder criterion for the study’s primary endpoint, and each achieved complete discontinuation of intravenous glucose with the administration of ersodetug.
  • FDA recommended that the Company file for review under a BLA for congenital HI after holding a pre-BLA meeting.

Concerns

  • The sunRIZE Phase 3 study in congenital HI did not meet its primary endpoint because reductions in hypoglycemia events by finger-stick SMBG were not statistically significant compared to placebo.
  • The eighth participant in the first half of the upLIFT study discontinued study drug shortly after enrollment to pursue hospice care at home and was considered a non-responder for the primary endpoint.
  • Cash, cash equivalents and investments in marketable securities declined to $90.0 million as of September 30, 2026, from $107.8 million as of June 30, 2026.
  • Net loss was $ (18,487 ) (in thousands), compared with $ (18,150 ) (in thousands) for the same period a year ago.
  • The Company stated there can be no assurance that FDA will agree that the totality of evidence from the sunRIZE program demonstrates a clinically meaningful benefit or is sufficient to support approval of ersodetug for congenital HI.

What to watch

  • Topline results from the tumor HI upLIFT study, expected by mid-December 2026.
  • The ongoing open-label extension phase of the sunRIZE study and indicators of glycemic control, including use of background standard of care therapies.
  • The planned BLA submission for ersodetug for one or potentially both indications in 2027.
  • Cash, cash equivalents and investments in marketable securities following the September 30, 2026 balance of $90.0 million.

Balance sheet and cash flow

  • Cash, cash equivalents and investments in marketable securities were $90.0 million as of September 30, 2026, compared with $107.8 million as of June 30, 2026.
  • Cash and cash equivalents were $ 8,150 (in thousands) as of September 30, 2026, compared with $ 10,615 (in thousands) as of June 30, 2026.
  • Investments in marketable debt securities were 81,849 (in thousands) as of September 30, 2026, compared with 97,186 (in thousands) as of June 30, 2026.
  • Working capital was 84,370 (in thousands) as of September 30, 2026, compared with 99,093 (in thousands) as of June 30, 2026.
  • Total stockholders’ equity was 85,948 (in thousands) as of September 30, 2026, compared with 100,687 (in thousands) as of June 30, 2026.

Analysis

Rezolute remains a development-stage company and reported no revenue in the filing. First-quarter fiscal 2027 operating expenses were $ 19,385 (in thousands), compared with $ 19,817 (in thousands) in the same period a year ago. R&D expense was $ 12,807 (in thousands), with the decline attributed to lower ersodetug manufacturing and patient-affairs costs, partly offset by higher employee-related stock-based compensation. G&A expense was $ 6,578 (in thousands), reflecting lower professional fees partly offset by higher employee-related stock-based compensation.

The lower operating expense base did not translate into a narrower reported net loss. Net loss was $ (18,487 ) (in thousands), compared with $ (18,150 ) (in thousands) a year earlier, as non-operating income, net declined to $ 898 (in thousands) from $ 1,667 (in thousands). Basic and diluted net loss per common share was unchanged at $ (0.18 ).

Liquidity declined during the quarter. Cash, cash equivalents and investments in marketable securities were $90.0 million at September 30, 2026, versus $107.8 million at June 30, 2026. The balance sheet also reported working capital of 84,370 (in thousands), total assets of 96,010 (in thousands), and total stockholders’ equity of 85,948 (in thousands) as of September 30, 2026.

The principal near-term clinical event is topline data from the tumor HI upLIFT Phase 3 study, expected by mid-December 2026. Enrollment is complete, and the Company said 7 of the 8 participants enrolled in the first half met the responder criterion for the primary endpoint; the remaining participant was classified as a non-responder after discontinuing study drug. For congenital HI, FDA recommended a BLA filing after a pre-BLA meeting, but sunRIZE did not meet its primary endpoint. The Company plans to submit a BLA for ersodetug for one or potentially both indications in 2027.

Not in the filing

stated, not guessed
  • Revenue and revenue comparisons were not reported.
  • Segment revenue and segment comparisons were not reported.
  • Gross margin was not reported.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Debt was not reported.
  • Capital returns, including share repurchases and dividends, were not reported.
  • Tax rate was not reported.
  • Financial guidance for revenue, gross margin, operating expenses, or tax rate was not reported.
  • Prior earnings outlook was not provided, so comparison with prior guidance is unavailable.
  • Named executive commentary and attributable executive quotes were not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Rezolute (Nasdaq: RZLT) is a late‑stage biotech focused on treating refractory hypoglycemia caused by hyperinsulinism.

Company-level read

Ticker impact

$RZLTBearishHigh confidence
Context

Rezolute filed its Q1 fiscal 2027 results, reporting a $18.5M net loss and cash down to $90M, plus updates on its ersodetug trials and upcoming BLA filing plans.

Expected impact

likely pressure as investors price in the widening loss and reduced cash balance

Evidence & confidence

First‑report earnings disclose a slightly larger loss and lower cash, which typically depresses a micro‑cap biotech's share price absent offsetting news.

Market effects

Highlights ongoing challenges for ultra‑rare metabolic disease biotech firms awaiting BLA decisions.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech community.

Counterpoint

If the BLA filing proceeds as planned, the stock could rebound despite short‑term earnings weakness.

Key entities

  • Rezolute, Inc.

    Biotech developer of ersodetug for hyperinsulinism.

  • FDA

    Agency reviewing additional data and discussing a pre‑BLA meeting.

Every RZLT earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$RZLTMed

Wedbush raises Rezolute stock price target on tumor trial data

Wedbush raised its price target for Rezolute Inc. (RZLT) to $10 from $6, citing positive Phase 3 trial data. The new target suggests 179% upside from the current $3.58 share price. The firm increased its success probability for hyperinsulinism treatments and adjusted its revenue forecasts. Rezolute recently completed enrollment in a Phase 3 study and has strong liquidity, according to InvestingPro.

$RZLTHighAI 8/10

Why is Rezolute stock surging today?

Rezolute's stock rose 7.8% pre-market after reporting positive Phase 3 trial results for ersodetug and a $100M equity offering at $3.87/share. The trial met its primary endpoint, with 13 of 16 participants reducing IV glucose needs. The offering, led by Frazier Life Sciences, is expected to close by November 16. The company plans FDA discussions for both indications in Q1 2027.